HERANTIS PHARMA OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.45 EUR | +2.11% |
|
+2.47% | -7.94% |
| 03-06 | Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-06 | Transcript : Herantis Pharma Oyj, 2023 Earnings Call, Mar 06, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 51.77 | 40.49 | 26.65 | 27.91 | 31.75 | 29.23 | - |
| Enterprise Value (EV) 1 | 51.99 | 34.37 | 26.65 | 27.91 | 31.75 | 25.03 | 29.23 |
| P/E ratio | -5.66 x | -3.35 x | -1.92 x | - | - | - | - |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 22.5 x | - |
| EV / Revenue | - | - | - | - | - | 19.3 x | - |
| EV / EBITDA | -8.51 x | -4.81 x | - | -3.56 x | 206 x | -8.34 x | - |
| EV / FCF | -8,725,099 x | -4,015,166 x | - | -3,048,427 x | - | - | - |
| FCF Yield | -0% | -0% | - | -0% | - | - | - |
| Price to Book | 28 x | 5.33 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 6,680 | 9,757 | 11,104 | 16,912 | 20,161 | 20,161 | - |
| Reference price 2 | 7.750 | 4.150 | 2.400 | 1.650 | 1.575 | 1.450 | 1.450 |
| Announcement Date | 20-02-27 | 21-03-03 | 22-03-03 | 23-03-28 | 24-03-06 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 1.3 | - |
| EBITDA 1 | -6.109 | -7.143 | - | -7.833 | 0.154 | -3 | - |
| EBIT 1 | -7.155 | -8.071 | - | -7.993 | 0.154 | -3 | -4 |
| Operating Margin | - | - | - | - | - | -230.77% | - |
| Earnings before Tax (EBT) 1 | -8.005 | -9.153 | - | -9.324 | 0.28 | -3.2 | -4 |
| Net income 1 | -8.005 | -9.153 | -12.77 | -9.324 | 0.28 | -3.2 | -4 |
| Net margin | - | - | - | - | - | -246.15% | - |
| EPS | -1.370 | -1.240 | -1.250 | - | - | - | - |
| Free Cash Flow | -5.958 | -8.561 | - | -9.154 | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 20-02-27 | 21-03-03 | 22-03-03 | 23-03-28 | 24-03-06 | - | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 0.21 | - | - | - | - | - | - |
| Net Cash position 1 | - | 6.12 | - | - | - | 4.2 | - |
| Leverage (Debt/EBITDA) | -0.035 x | - | - | - | - | - | - |
| Free Cash Flow | -5.96 | -8.56 | - | -9.15 | - | - | - |
| ROE (net income / shareholders' equity) | -909% | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | 0.2800 | 0.7800 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 20-02-27 | 21-03-03 | 22-03-03 | 23-03-28 | 24-03-06 | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.94% | 31.48M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- HRTIS Stock
- Financials Herantis Pharma Oyj